Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced that the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) has granted authorization in the United Kingdom (U.K.) for molnupiravir (MK-4482, EIDD-2801), the first oral antiviral medicine authorized for the treatment of mild-to-moderate COVID-19 in adults with a positive SARS-CoV-2 diagnostic test and who have at least one risk factor for developing severe illness.
Merck and Ridgeback’s molnupiravir, an oral COVID-19 antiviral medicine, receives first authorization in the world
November 15, 2021
Related blog posts
New drug shows promise for fighting both COVID-19 and cancer
November 15, 2022